Results

1–10 of 14 results for DERBY

Impact of AREDS Oral Micronutrient Supplementation on Geographic Atrophy Progression: Insights From thePhase 3 OAKS and DERBY Trials
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2025
Clinical Utility of the Fellow Eye in Patients With Bilateral GA Due to AMD: Long-Term Data from thePegcetacoplan Clinical Program
Diana V Do, MD, FASRS
Annual Meeting Talks
2025
Early vs Delayed Pegcetacoplan Treatment for GA Secondary to AMD: 48-Month Results From OAKS, DERBY,and GALE Open-Label Extension
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2025
Baseline Characteristics Associated With Geographic Atrophy Progression in the OAKS and DERBY Trials
Srinivas Reddy Sadda, MD
Annual Meeting Talks
2025
Exudative Age-Related Macular Degeneration Events from the OAKS and DERBY Clinical Trials of Pegcetacoplan in Geographic Atrophy
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2023
Long-Term Efficacy of Pegcetacoplan in Patients With Geographic Atrophy
Nathan C. Steinle, MD
Annual Meeting Talks
2023
Expert Panel: Pegcetacoplan Safety
Andre J. Witkin, MD
David A. Eichenbaum, MD, FASRS
Samuel Anthony Minaker, MD, MSc
Janani Singaravelu, MS, MD
Sunir J. Garg, MD, FACS, FASRS
Annual Meeting Talks
2024
Relationship Between Number of Intermediate-Large Drusen and Geographic Atrophy Lesion Growth Rate in the Sham Groups of the DERBY, OAKS, and FILLY Trials
Eleonora Lad, MD, PhD
Annual Meeting Talks
2022
Safety of Intravitreal Pegcetacoplan for Geographic Atrophy: 12-Month Results of the OAKS and DERBY Trials
Caroline Baumal, MD, FASRS
Annual Meeting Talks
2022
Detailed Baseline Demographics and Disease Characteristics of Patients With Geographic Atrophy Enrolled in the Phase 3 OAKS and DERBY Clinical Trials
On Demand Cases, Courses, and Papers
2022